NDAORALTABLET
Approved
Nov 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEVETEN HCT is a fixed-dose combination tablet containing eprosartan mesylate (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic) approved for treating hypertension. It combines two complementary antihypertensive mechanisms—ARB-mediated vasodilation and diuretic fluid reduction—to achieve blood pressure control in patients requiring dual therapy.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a mature brand with limited growth opportunities and likely streamlined team structures.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TEVETEN HCT currently shows zero linked job openings, consistent with its LOE-approaching lifecycle stage and mature market position. Career opportunities on this product are likely limited to defensive/maintenance roles (managed care, authorized generic support, or niche indication management) rather than growth-focused positions.
Brand ManagerField Sales Representative
Worked on TEVETEN HCT at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.